CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
Empagliflozin 25 MGdrug
Likely dose
Empagliflozin 25 MGfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04907214
NCT04907214Phase 2Completed
CompareCT.gov

The Effect of SGLT2 Inhibition on Adipose Tissue Inflammation and Endothelial Function Pilot

Vanderbilt University Medical Center·interventional·Posted May 28, 2021·Updated Dec 29, 2023

In Brief

A Phase 2 clinical trial evaluating Empagliflozin 25 MG for Obesity and Pre-diabetes. Completed, enrolled 29 participants across 1 site.

Detailed Summary

Obesity is associated with increased cardiometabolic disease risk due, in part, to heightened chronic inflammation arising from adipose tissue. There are no current targeted therapies to prevent or reverse the chronic inflammation of obesity, and a better understanding of these inflammatory pathways in humans is key to future therapeutic interventions. This project will determine both the anti-inflammatory potential of the SGLT2 inhibitor empagliflozin, and the contribution of adipose inflammation to surrogate measures of cardiovascular disease in a randomized controlled trial of obese patients.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsObesity, Pre-diabetes
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedMay 28, 2021
Enrollment StartJul 29, 2021
Primary CompletionDec 8, 2023
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 5.1 years ago

Interventions

Empagliflozin 25 MGdrug

Oral empagliflozin daily